by Annie Deck-Miller
Roswell Park Cancer Institute (RPCI) has received U.S. Food and Drug Administration (FDA) approval to enroll patients in a phase II clinical trial that will use a unique and highly precise method of delivering interstitial photodynamic therapy (I-PDT) to recurrent tumors of the head and neck.
Most patients with recurrent and nonresectable head-and-neck cancer experience poor quality of life and a projected survival that is measured in months. I-PDT is an additional treatment option that may improve outcomes for patients who respond poorly to standard therapies.
"These patients have no effective treatment options," says Gal Shafirstein, DSc, principal investigator of the study and a member of RPCI's Departments of Cell Stress Biology and Head & Neck/Plastic & Reconstructive Surgery. "We hope to learn through this study whether we can improve their overall survival by adding interstitial photodynamic therapy to standard treatment approaches."
PDT, a treatment approach developed at RPCI, uses laser light to activate a nontoxic drug called a photosensitizer. The process works in three ways: it destroys cancer, shuts down blood vessels that "feed" the tumor, and prompts the immune system to kill cancer cells throughout the body. It is associated with mild side effects and can be combined with standard chemotherapy and surgery, and followed with radiation therapy.
Initiated by Dr. Shafirstein, the phase II clinical trial will use the photosensitizer Photofrin, manufactured by Pinnacle Biologics, Inc., which is funding the trial. The study will be conducted in collaboration with Thomas Foster, PhD, and Timothy Baran, PhD, both of the Department of Imaging Sciences at the University of Rochester Medical Center.
Treating physician Hassan Arshad, MD, a surgical oncologist in RPCI's Department of Head & Neck/Plastic & Reconstructive Surgery, will be responsible for all clinical aspects of the study.
The clinical trial will borrow treatment-delivery techniques already used in the field of radiation medicine. Advanced treatment planning developed specifically for I-PDT will help the team to calculate the precise dose of laser light needed for each section of a tumor. That information will be used to treat tumors while minimizing damage to healthy tissue.
Patients enrolled in the study will undergo pretreatment imaging with computed tomography (CT). A three-dimensional image of the tumor will then be created with CT scans to determine the number and correct placement of the optical fibers that will deliver the laser light. The patients will receive Photofrin, followed by a two-day waiting period to allow the photosensitizer to be absorbed by the cancer cells. The treatment will be conducted while the patient is under general anesthesia. The optical fibers will be inserted through the skin and into the tumor at specific, predetermined points. A light-dosimetry system developed by Dr. Shafirstein in his RPCI lab will measure, in real time, the light being delivered by each optic fiber, giving the medical team the information needed to make necessary adjustments to meet the goals of the treatment plan.
"Collaborating with Roswell Park is an important step in expanding our clinical development platform for PDT with Photofrin," says Mark Thompson, chief executive officer of Concordia Healthcare Corp., parent company of Pinnacle Biologics. "Increased education, awareness and use of the dosimetry device, and the statistically significant outcomes we have achieved in other rare and hard-to-treat cancers, will inform this process and will, we hope, lead to better and more options for critically ill patients."
"We hope that these state-of-the-art approaches will maximize the potential benefit of this therapy for patients with recurrent head and neck tumors," Dr. Shafirstein adds.
Explore further: Biomarkers predict effectiveness of radiation treatments for cancer
Medical Xpress on facebook
Related Stories
Biomarkers predict effectiveness of radiation treatments for cancer
Mar 27, 2014
An international team of researchers, led by Beaumont Health System's Jan Akervall, M.D., Ph.D., looked at biomarkers to determine the effectiveness of radiation treatments for patients with squamous cell cancer of the head ...
Biochips for better cancer therapy
Feb 25, 2014
Cancer is the second leading cause of disease-related death in the United States, and may overtake heart disease without aggressive new therapies. One promising area of cancer treatment is photodynamic therapy ...
Surgery beats chemotherapy for tongue cancer, study finds
Dec 26, 2013
Patients with tongue cancer who started their treatment with a course of chemotherapy fared significantly worse than patients who received surgery first, according to a new study from researchers at the University ...
Bevacizumab does not extend lives of newly diagnosed glioblastoma patients
Mar 06, 2014
(Medical Xpress)—Results from a randomized, phase 3 clinical trial conducted by the Radiation Therapy Oncology Group (RTOG) have shown that adding bevacizumab, a drug that inhibits the growth of blood vessels, to the treatment ...
Combining CT, FDG-PET provides more accurate treatments for head and neck cancer patients
Apr 29, 2011
Combining computerized tomography (CT) with fluorodeoxyglucose positron emission tomography (FDG-PET) images results in significantly more defined tumor outlines and potentially different treatment options in head and neck ...
Recommended for you
Three DNA methylation markers ID recurrence in bladder cancer
1 hour ago
(HealthDay)—For patients with noninvasive urothelial carcinoma, three DNA methylation markers are able to accurately predict tumor recurrence, according to a study published in the April 1 issue of Clinical Ca ...
World-first clinical trial launches for advanced bowel cancer
1 hour ago
Patients with advanced bowel cancer are set to benefit from the launch of a revolutionary new clinical trial targeting treatments to their specific cancer type as well as rapidly adapting to include new drugs ...
Cell metabolism discovery could lead to treatments for cancer, common cold
2 hours ago
(Medical Xpress)—Scientists at UCLA's Jonsson Comprehensive Cancer Center have published the first study explaining in detail how viruses reprogram the metabolism of the cells they invade to promote continued viral growth ...
The Sun's campaign may actually harm women
14 hours ago
A breast check campaign by The Sun newspaper may actually harm women, warns Glasgow general practitioner Margaret McCartney today.
Screening for liver cancer in patients with cirrhosis
15 hours ago
In a systematic review and meta-analysis of 47 studies with 15,158 patients, Amit Singal (University of Texas Southwestern Medical Center) and colleagues found that patients with cirrhosis who underwent surveillance (via ...
Likely culprit in spread of colon cancer identified
15 hours ago
New research at Washington University School of Medicine in St. Louis and Vanderbilt University Medical Center in Nashville has implicated a poorly understood protein called PLAC8 in the spread of colon cancer.
User comments
© Medical Xpress 2011-2014, Science X network
by Annie Deck-Miller
Roswell Park Cancer Institute (RPCI) has received U.S. Food and Drug Administration (FDA) approval to enroll patients in a phase II clinical trial that will use a unique and highly precise method of delivering interstitial photodynamic therapy (I-PDT) to recurrent tumors of the head and neck.
Most patients with recurrent and nonresectable head-and-neck cancer experience poor quality of life and a projected survival that is measured in months. I-PDT is an additional treatment option that may improve outcomes for patients who respond poorly to standard therapies.
"These patients have no effective treatment options," says Gal Shafirstein, DSc, principal investigator of the study and a member of RPCI's Departments of Cell Stress Biology and Head & Neck/Plastic & Reconstructive Surgery. "We hope to learn through this study whether we can improve their overall survival by adding interstitial photodynamic therapy to standard treatment approaches."
PDT, a treatment approach developed at RPCI, uses laser light to activate a nontoxic drug called a photosensitizer. The process works in three ways: it destroys cancer, shuts down blood vessels that "feed" the tumor, and prompts the immune system to kill cancer cells throughout the body. It is associated with mild side effects and can be combined with standard chemotherapy and surgery, and followed with radiation therapy.
Initiated by Dr. Shafirstein, the phase II clinical trial will use the photosensitizer Photofrin, manufactured by Pinnacle Biologics, Inc., which is funding the trial. The study will be conducted in collaboration with Thomas Foster, PhD, and Timothy Baran, PhD, both of the Department of Imaging Sciences at the University of Rochester Medical Center.
Treating physician Hassan Arshad, MD, a surgical oncologist in RPCI's Department of Head & Neck/Plastic & Reconstructive Surgery, will be responsible for all clinical aspects of the study.
The clinical trial will borrow treatment-delivery techniques already used in the field of radiation medicine. Advanced treatment planning developed specifically for I-PDT will help the team to calculate the precise dose of laser light needed for each section of a tumor. That information will be used to treat tumors while minimizing damage to healthy tissue.
Patients enrolled in the study will undergo pretreatment imaging with computed tomography (CT). A three-dimensional image of the tumor will then be created with CT scans to determine the number and correct placement of the optical fibers that will deliver the laser light. The patients will receive Photofrin, followed by a two-day waiting period to allow the photosensitizer to be absorbed by the cancer cells. The treatment will be conducted while the patient is under general anesthesia. The optical fibers will be inserted through the skin and into the tumor at specific, predetermined points. A light-dosimetry system developed by Dr. Shafirstein in his RPCI lab will measure, in real time, the light being delivered by each optic fiber, giving the medical team the information needed to make necessary adjustments to meet the goals of the treatment plan.
"Collaborating with Roswell Park is an important step in expanding our clinical development platform for PDT with Photofrin," says Mark Thompson, chief executive officer of Concordia Healthcare Corp., parent company of Pinnacle Biologics. "Increased education, awareness and use of the dosimetry device, and the statistically significant outcomes we have achieved in other rare and hard-to-treat cancers, will inform this process and will, we hope, lead to better and more options for critically ill patients."
"We hope that these state-of-the-art approaches will maximize the potential benefit of this therapy for patients with recurrent head and neck tumors," Dr. Shafirstein adds.
Explore further: Biomarkers predict effectiveness of radiation treatments for cancer
Medical Xpress on facebook
Related Stories
Biomarkers predict effectiveness of radiation treatments for cancer
Mar 27, 2014
An international team of researchers, led by Beaumont Health System's Jan Akervall, M.D., Ph.D., looked at biomarkers to determine the effectiveness of radiation treatments for patients with squamous cell cancer of the head ...
Biochips for better cancer therapy
Feb 25, 2014
Cancer is the second leading cause of disease-related death in the United States, and may overtake heart disease without aggressive new therapies. One promising area of cancer treatment is photodynamic therapy ...
Surgery beats chemotherapy for tongue cancer, study finds
Dec 26, 2013
Patients with tongue cancer who started their treatment with a course of chemotherapy fared significantly worse than patients who received surgery first, according to a new study from researchers at the University ...
Bevacizumab does not extend lives of newly diagnosed glioblastoma patients
Mar 06, 2014
(Medical Xpress)—Results from a randomized, phase 3 clinical trial conducted by the Radiation Therapy Oncology Group (RTOG) have shown that adding bevacizumab, a drug that inhibits the growth of blood vessels, to the treatment ...
Combining CT, FDG-PET provides more accurate treatments for head and neck cancer patients
Apr 29, 2011
Combining computerized tomography (CT) with fluorodeoxyglucose positron emission tomography (FDG-PET) images results in significantly more defined tumor outlines and potentially different treatment options in head and neck ...
Recommended for you
Three DNA methylation markers ID recurrence in bladder cancer
1 hour ago
(HealthDay)—For patients with noninvasive urothelial carcinoma, three DNA methylation markers are able to accurately predict tumor recurrence, according to a study published in the April 1 issue of Clinical Ca ...
World-first clinical trial launches for advanced bowel cancer
1 hour ago
Patients with advanced bowel cancer are set to benefit from the launch of a revolutionary new clinical trial targeting treatments to their specific cancer type as well as rapidly adapting to include new drugs ...
Cell metabolism discovery could lead to treatments for cancer, common cold
2 hours ago
(Medical Xpress)—Scientists at UCLA's Jonsson Comprehensive Cancer Center have published the first study explaining in detail how viruses reprogram the metabolism of the cells they invade to promote continued viral growth ...
The Sun's campaign may actually harm women
14 hours ago
A breast check campaign by The Sun newspaper may actually harm women, warns Glasgow general practitioner Margaret McCartney today.
Screening for liver cancer in patients with cirrhosis
15 hours ago
In a systematic review and meta-analysis of 47 studies with 15,158 patients, Amit Singal (University of Texas Southwestern Medical Center) and colleagues found that patients with cirrhosis who underwent surveillance (via ...
Likely culprit in spread of colon cancer identified
15 hours ago
New research at Washington University School of Medicine in St. Louis and Vanderbilt University Medical Center in Nashville has implicated a poorly understood protein called PLAC8 in the spread of colon cancer.
User comments
© Medical Xpress 2011-2014, Science X network
0 comments:
Post a Comment